Share on StockTwits

Alkermes Plc (NASDAQ:ALKS) SVP Kathryn L. Biberstein sold 8,400 shares of Alkermes Plc stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $47.41, for a total transaction of $398,244.00. Following the completion of the transaction, the senior vice president now directly owns 69,783 shares of the company’s stock, valued at approximately $3,308,412. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Alkermes Plc (NASDAQ:ALKS) traded up 0.49% during mid-day trading on Wednesday, hitting $47.23. The stock had a trading volume of 662,874 shares. Alkermes Plc has a 1-year low of $26.47 and a 1-year high of $54.25. The stock has a 50-day moving average of $46.17 and a 200-day moving average of $45.60. The company’s market cap is $6.825 billion.

Alkermes Plc (NASDAQ:ALKS) last announced its earnings results on Wednesday, April 30th. The company reported $0.11 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.10 by $0.01. The company had revenue of $130.21 million for the quarter, compared to the consensus estimate of $135.79 million. During the same quarter in the prior year, the company posted $0.40 earnings per share. The company’s quarterly revenue was down 20.3% on a year-over-year basis. On average, analysts predict that Alkermes Plc will post $0.49 earnings per share for the current fiscal year.

ALKS has been the subject of a number of recent research reports. Analysts at Jefferies Group initiated coverage on shares of Alkermes Plc in a research note on Friday, May 16th. They set a “buy” rating and a $53.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Alkermes Plc in a research note on Friday, May 2nd. They now have a $50.00 price target on the stock. Finally, analysts at Zacks downgraded shares of Alkermes Plc from an “outperform” rating to a “neutral” rating in a research note on Wednesday, April 16th. They now have a $45.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $47.00.

Alkermes Public Limited Company is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (NASDAQ:ALKS) disorders such as addiction, schizophrenia and depression.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.